Elevated Soluble Tumor Necrosis Factor Receptor 75 Concentrations Identify Patients With Liver Cirrhosis at Risk of Death

Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension

“…Even though no major changes were observed in the levels of the sTNFRs levels after TIPS, the levels of sTNFRs correlated with parameters of liver dysfunction, confirming our previous data [31], [32]. In a previous study in patients with alcoholic liver cirrhosis receiving TIPS levels of endotoxin in the portal vein correlated with the levels of sTNFR in the hepatic vein, suggesting an association between endotoxin exposure and formation of sTNFR [31].…”

“…However, sTNFRs in peripheral blood might be also suitable and their predictive potential should be evaluated in future studies in TIPS patients, as already shown by our group for sTNFR levels in the peripheral blood of non-TIPS patients [32]. Interestingly, hepatic sTNFR-I levels after TIPS are associated with long-term survival together with Child-score (Table 4).…”

“…Blood samples were centrifuged at 3000 rpm for 15 minutes at 4°C and stored at −80°C. In the plasma samples, levels of soluble tumor necrosis factor αreceptors Type I (55 kD or CD120a) and Type II (75 kD or CD120b) were measured by enzyme-amplified immunoassays following the instructions of the manufacturer (Medgenix Diagnostics, Fleurus, Belgium) [31], [32].…”

“…In patients hepatic venous levels of soluble TNFα receptors correlated with the portal endotoxin influx [31]. Furthermore, the levels of sTNFR-II were found to be good predictors of mortality in patients with liver cirrhosis [32]. However, the prognostic potential of sTNFRs has not yet been studied in patients with respect to severity of portal hypertension before and after TIPS-insertion.…”

Gene Polymorphism of Proinflammatory Cytokines (Tnf, Il6) and Their Receptors (Tnfrsf1a, Tnfrsf1b, Il6r): Implications for Non-Alcoholic Fatty Liver Disease

“…В связи с этим уровни растворимых рецепторов TNFRI и TNFRII пред-лагается использовать в клинике как маркеры тяжести заболеваний и прогностические пока-затели [Tokushigе et al, 2007]. Например, пока-зано, что у пациентов с циррозом печени хоро-ший прогноз относительно смертности связан с повышенным содержанием в плазме рас-творимых TNFRII-рецепторов [Grunhage et al, 2008]. Содержание растворимых TNFR может быть использовано также как маркер эффек-тивности лечения иммунномодулирующими препаратами пациентов с заболеваниями пе-чени, в частности вирусным гепатитом С [Zekri et al, 2007].…”